Form 4: Rapport Therapeutics Director Receives Stock Option Grant

Director Ramiro Sanchez was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Ramiro Sanchez acquired 15,200 stock options in Rapport Therapeutics, Inc. (RAPP).
• The options have an exercise price of $35.21 per share.
• The grant date is June 10, 2026, with an expiration date of June 10, 2036.
• The options are subject to a vesting schedule based on the earlier of one year or the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility could impact the value of the options relative to the exercise price.
• Vesting is contingent upon continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The options vest on the earlier of June 10, 2027, or the date of the next Annual Meeting of Stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance and long-term strategic goals.

Comparison to Industry Standards

• The grant size and vesting terms are consistent with standard equity compensation packages for directors in mid-cap biotechnology firms.
• The use of a one-year cliff or annual meeting vesting cycle is a common benchmark for board compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon future exercise of options.
• Director: Increased financial stake in the company's long-term performance.

Next Steps

• Vesting of options on June 10, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Director Compensation, Stock Options, Insider Transaction, SEC Form 4